Hospital Mater Dei SA
BOVESPA:MATD3

Watchlist Manager
Hospital Mater Dei SA Logo
Hospital Mater Dei SA
BOVESPA:MATD3
Watchlist
Price: 4.74 BRL -3.27% Market Closed
Market Cap: 1.6B BRL

Hospital Mater Dei SA
Investor Relations

Hospital Mater Dei SA engages in the provision of health care services. The company is headquartered in Belo Horizonte, Minas Gerais. The company went IPO on 2021-04-16. The firm has hospital beds distributed in its four units strategically located in the metropolitan region of Belo Horizonte and in Belem, in addition to hospital beds in the Hospital de Salvador/BA, Hospital Santa Genoveva in Uberlandia/MG, Hospital Premium in Goiania/GO and Hospital EMEC in Feira de Santana/BA. The firm provides services to several independent and self-managed health plan operators, such as: Allianz, Amil, Bacen, Bradesco Saude, Caixa Economica Federal, Care Plus, Cassi, Copass, FCA Saude, Golden Cross, IPSM, Sul America, Vale, among many others.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2025
Call Date
Aug 14, 2025
AI Summary
Q2 2025

Record Revenue: Mater Dei surpassed BRL 500 million in quarterly revenue for the first time, reaching BRL 546 million, driven by improved procedure mix and operational efficiency.

EBITDA Growth: EBITDA rose to BRL 150 million, up 32% from Q2 2024, with EBITDA margin increasing to 21.1%.

Occupancy & Productivity: Hospital occupancy hit 83%, maintained without adding significant new beds, reflecting higher operational productivity.

Cost Control: Cost ratios fell below 70% of revenue, and operational expenses dropped to 14.1%, aided by staff resizing and administrative streamlining.

Cash Generation & Debt: Net debt fell by BRL 35 million, leverage remained healthy at 1.6x, and favorable debt refinancing reduced rates by 50 bps.

Unit Ramp-Up: Salvador and Nova Lima hospitals posted strong revenue and patient growth, with Salvador’s net revenue up 25% and oncological patients up 79% year-on-year.

Positive Outlook: Management expects continued improvement in the second half, focusing on revenue quality, cash flow, and ongoing operational gains.

Key Financials
Net Revenue
BRL 546 million
EBITDA
BRL 150 million
EBITDA Margin
21.1%
Occupancy Rate
83%
Net Profit
BRL 27 million
Net Debt
BRL 664 million
Leverage
1.6x
Patient Volume (hospitalized)
87,369 patients
Average Revenue Per Patient Day
BRL 6,980
Cost Ratio
below 70%
Operational Expenses Ratio
14.1%
NPS (Network-wide)
73%
NPS (Salvador Unit)
above 75%
Debt Refinancing Rate
CDI + 1.10%
Earnings Call Recording
Other Earnings Calls

Management

Mr. Jose Henrique Dias Salvador
Chief Executive Officer
No Bio Available
Mr. Rafael Cardoso Cordeiro
Chief Financial & Investor Relations Officer
No Bio Available
Ms. Marcia Salvador Geo
Vice President of Operational Assistance & Clinical Director
No Bio Available
Ms. Maria Norma Salvador Ligorio
Vice President of Administrative & Commercial
No Bio Available
Ms. Maria Fernanda Veloso Pires
Member of the Audit & Risk Committee and Board Secretary
No Bio Available

Contacts

Address
MINAS GERAIS
Belo Horizonte
Rua Mato Grosso n 1100, Santo Agostinho
Contacts
+553133399221
www.materdei.com.br